Novo Nordisk’s Semaglutide Shows Promise In Hidradenitis Suppurativa
Executive Summary
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.